IDH-mutant glioma
Oncology · 2025–2026
2decisions
1medicine
1carried consumer input
107individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| vorasidenib Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma with residual or recurrent disease after at least one prior surgery, who are… | Mar 2026 | Recommended with restriction | no section in document |
| vorasidenib Treatment of patients with WHO Grade 2 IDH-mutant astrocytoma or oligodendroglioma who have residual or recurrent disease after at least one prior surgery and… | Jul 2025 | Not recommended | 107 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.